Pertussis vaccine - ILiAD/INSERM

Drug Profile

Pertussis vaccine - ILiAD/INSERM

Alternative Names: BPZE 1

Latest Information Update: 07 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM; Institut Pasteur
  • Developer ILiAD Biotechnologies; INSERM; Institut Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Pertussis

Most Recent Events

  • 05 Jul 2017 Preclinical development in Pertussis is ongoing in France
  • 05 Jul 2017 ILiAD Biotechnologies has patent protection for BPZE1 technology
  • 05 Jul 2017 ILiAD Biotechnologies has patents pending for BPZE1 technology worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top